ArticleCureus2026
Episodic Ataxia Associated With Synaptosomal-Associated Protein 25 (SNAP25) Variant: Beyond Epilepsy and Developmental Delay.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Developmental and epileptic encephalopathies (DEEs) of infancy and childhood are characterized by early-onset seizures and developmental impairment. Heterozygous missense or loss-of-function variants in synaptosomal-associated protein 25 (SNAP25), a core component of the presynaptic soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex, have been implicated in a spectrum of DEEs with variable neurological features. We report a male child carrying a novel de novo splice-site variant in SNAP25, expanding the known mutational and phenotypic spectrum of this condition. The patient presented at 32 months with afebrile seizures since seven months of age, with frequent seizure clusters and status epilepticus. He exhibited a moderate global developmental delay and recurrent, transient episodes of gait ataxia triggered by febrile illnesses, lasting up to one week and resolving without residual deficits. Neurological examination revealed mild microcephaly and a clumsy gait without persistent ataxia or weakness between febrile episodes. Brain magnetic resonance imaging (MRI) was normal, and the electroencephalogram (EEG) showed bilateral frontal paroxysmal activity. Genetic testing identified a heterozygous SNAP25 variant (NM_003081.5:c.114+2dup), predicted to abolish the donor splice site and confirmed as de novo, classified as likely pathogenic. The patient achieved complete seizure control under levetiracetam monotherapy and continues to show moderate global developmental delay. This case broadens the genotypic and phenotypic spectrum of SNAP25-related DEE, highlighting febrile illness-triggered episodic ataxia as a previously unreported manifestation. It underscores the relevance of recognizing transient neurological decompensations in the context of SNARE complex dysfunction and highlights the potential for meaningful neurodevelopmental progress despite early epileptic encephalopathy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.